Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901, as PT Ferron Par Pharmaceuticals will become our exclusive partner in Indonesia, effective January 1, 2025.

This new partnership marks a critical step forward in Moleac’s commitment to expanding the availability of innovative treatments for stroke recovery, traumatic brain injuries, and neurodegenerative diseases. As a member of Dexa Group, PT Ferron Par Pharmaceuticals brings deep market expertise and a reputation for operational excellence, positioning them as the ideal partner to lead the commercial distribution of NeuroAiD II MLC901 in Indonesia.

"We are thrilled to welcome PT Ferron Par Pharmaceuticals as our exclusive partner in Indonesia. Their leadership and expertise in the pharmaceutical industry will help accelerate our mission to improve patient outcomes through wider access to NeuroAiD II MLC901," said David Picard, CEO of Moleac.

Moleac extends its heartfelt gratitude to PT Mersifarma Tirmaku Mercusana for their invaluable contributions over the past 12 years, during which they played a pivotal role in introducing NeuroAiD to the Indonesian market. Their support has been instrumental in laying the foundation for this next chapter of growth.

As we embark on this new chapter with PT Ferron Par Pharmaceuticals, Moleac is confident that the partnership will enhance the availability of NeuroAiD II MLC901, making it accessible to more patients in need. This collaboration represents a crucial step in our continued efforts to support healthcare professionals and improve recovery outcomes for patients affected by neurological conditions.